STOCK MARKET BSE NSE

Covid-19: Russia ties up with Dr Reddy's for vaccine trial in India, to supply 10 crore doses by December

Upon regulatory approval in India, Russia's sovereign wealth fund will supply 100 million doses of the vaccine to Dr Reddy's Laboratories.

Published: 16th September 2020 04:07 PM  |   Last Updated: 16th September 2020 05:41 PM   |  A+A-

Sputnik V, Russia covid-19 vaccine,

A new vaccine is on display at the Nikolai Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia. (Photo | AP)

By Express News Service

NEW DELHI: Russia on Wednesday announced its partnership with Hyderabad-based Dr Reddy’s Laboratories for clinical trials and distribution of its Covid-19 vaccine 'Sputnik V' in India by the year-end.

Under the plan, the Russian Direct Investment Fund (RDIF), which is leading the Covid-19 vaccine project in India, will supply 10 crore doses to Dr Reddy’s upon regulatory approval.

“Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India,” said a joint statement by the RDIF and Dr Reddy’s.

ALSO READ | Fresh hope as Donald Trump says coronavirus vaccine could be ready in a month

G V Prasad, Co-Chairman and Managing Director of Dr Reddy’s said that the company will be conducting Phase-III trials in the country to meet the requirements of the Indian regulators. “Sputnik V vaccine could provide a credible option in our fight against Covid- 19 in India,” he said.

Significantly, the development comes days after Union Health Minister Harsh Vardhan said that the government is considering emergency use authorisation of Covid-19 vaccine in India, particularly for senior citizens and people working in high-risk settings.

Sputnik V was found to be safe and effective on a small group of volunteers in Russia in phase 1 and 2 trials, as per a paper recently published in the Lancet. The vaccine candidate is currently under phase 3 trials involving 40,000 individuals.

ALSO READ | Centre considering phase 3 trial of Russian Covid-19 vaccine in India: Niti Aayog member

CEO of the RDIF Kirill Dmitriev said that as India is amongst the most severely Covid-affected countries, the Russian human adenovirus dual vector platform could provide a safe and scientifically validated option to the country in the battle against the pandemic.

“The platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”

Sources in the RDIF said that it was planning to approach the Central Drugs Standards Control Organisation shortly to begin late-stage trials in the country, and added that it is also in talks with several other Indian vaccine-makers for large-scale productions.

ALSO READ | US states told be ready to distribute Covid-19 vaccine by November 1

The Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the ministry of health of Russia on August 11 and became the world’s first registered vaccine against Covid-19.

RDIF said that more than 55,000 volunteers have applied to take part in post-registration trials and the first results of these trials are expected to be published in October-November.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp